Elan Announces Commencement of SEC Investigation

Search Blogs that Mention this News Release

Click this link to view linked Bookmarking Services

Click this link to view linked Blogging Services

Elan Announces Commencement of SEC Investigation

    DUBLIN, Ireland, Feb. 7 /PRNewswire-FirstCall/ -- Elan Corporation, plc
(NYSE: ELN) ("Elan") announced today that it has been notified by the staff of
the Securities and Exchange Commission that the staff is commencing an
investigation relating to the Company.  The Company welcomes the opportunity
to resolve all matters raised by the SEC in light of recent allegations made
against the Company in the media and in shareholder lawsuits.
    Elan Corporation, plc is a leading worldwide, fully integrated
biopharmaceutical company headquartered in Ireland, with its principal
research, development, manufacturing and marketing facilities located in
Ireland, the United States and the United Kingdom.  Elan is focused on the
marketing of therapeutic products and services in neurology, pain management,
oncology, infectious disease and dermatology and on the development and
commercialization of products using its extensive range of proprietary drug
delivery technologies.  Elan shares trade on the New York, London and Dublin
Stock Exchanges.

SOURCE Elan Corporation, plc

http://www.elan.ie
Company News On-Call:

http://www.prnewswire.com/comp/231593.html
CONTACT:
Investors - (U.S.) - Jack Howarth,
+1-212-407-5740, or +1-800-252-3526, Investors - (Europe) - Emer
Reynolds, +353-1-709-4000, or +00800-28352600, Media - Max
Gershenoff, +1-212-407-5751, +1-800-252-3526, all of Elan
Corporation, plc